The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

(2019) Jianping Liu et al.   Small

Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes

(2019) Yanheng Wu et al.   Nanomedicine

Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy

(2019) Anna Galstyan et al.   Nature Communications

Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments

(2018) Yang Du et al.   CANCER LETTERS

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy

(2018) Yinghao Zhao et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(2018) Andrew X Zhu et al.   LANCET ONCOLOGY

Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy

(2018) Chih-Sheng Chiang et al.   Nature Nanotechnology

Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy

(2018) Wen Cheng et al.   Oncogenesis

Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy

(2018) Qin Fan et al.   ADVANCED FUNCTIONAL MATERIALS

Immune Checkpoint Inhibitor Toxicity

(2018) David J. Palmieri et al.   Current Oncology Reports

Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy

(2018) Sara Musetti et al.   ACS Nano

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC

(2018) Lillian L. Siu et al.   JAMA Oncology

Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy

(2018) Quanyin Hu et al.   Nature Biomedical Engineering

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape

(2017) Leisha A. Emens et al.   EUROPEAN JOURNAL OF CANCER

Evaluation of PLGA containing anti -CTLA4 inhibited endometriosis progression by regulating CD4 + CD25 + Treg cells in peritoneal fluid of mouse endometriosis model

(2017) Qi Liu et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

The new era of nanotechnology, an alternative to change cancer treatment

(2017) Ancuta Jurj et al.   Drug Design Development and Therapy

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

(2017) Hashem O. Alsaab et al.   Frontiers in Pharmacology

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?

(2017) Zijun Y. Xu-Monette et al.   Frontiers in Immunology

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

(2017) Thomas Powles et al.   JAMA Oncology

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

(2016) Christophe Massard et al.   JOURNAL OF CLINICAL ONCOLOGY

Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation

(2016) Shi-Yong Li et al.   JOURNAL OF CONTROLLED RELEASE

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody

(2016) Chao Wang et al.   NANO LETTERS

Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood

(2016) Katrin Klocke et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy

(2016) Hong-Jun Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Improving the clinical impact of biomaterials in cancer immunotherapy

(2016) Joshua M. Gammon et al.   Oncotarget

PD-1 Blockade Expands Intratumoral Memory T Cells

(2016) A. Ribas et al.   Cancer Immunology Research

Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports

(2016) Noha Abdel-Wahab et al.   PLoS One

Blocking of the PD-1/PD-L1 Interaction by aD-Peptide Antagonist for Cancer Immunotherapy

(2015) Hao-Nan Chang et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors

(2015) T. W. Chen et al.   ANNALS OF ONCOLOGY

Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer

(2015) Sima Rahimian et al.   BIOMATERIALS

PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia

(2015) F. McClanahan et al.   BLOOD

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

(2015) Anne Bertrand et al.   BMC Medicine

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

(2015) A. Patnaik et al.   CLINICAL CANCER RESEARCH

Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012.

(2015) Kei Muro et al.   JOURNAL OF CLINICAL ONCOLOGY

Toxicities of Immunotherapy for the Practitioner

(2015) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

(2015) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity

(2015) Alison M. Paterson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma

(2015) Matthew M. K. Chan et al.   JOURNAL OF IMMUNOTHERAPY

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ovarian Cancer Immunotherapy Using PD-L1 siRNA Targeted Delivery from Folic Acid-Functionalized Polyethylenimine: Strategies to Enhance T Cell Killing

(2015) Pei Yun Teo et al.   Advanced Healthcare Materials

Drug-Associated Dermatomyositis Following Ipilimumab Therapy

(2015) Shirwa Sheik Ali et al.   JAMA Dermatology

Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity

(2015) Yongkui Li et al.   OncoImmunology

Abstract CT105: MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression

(2015) Leena Gandhi et al.   CANCER RESEARCH

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer

(2015) Jiabei He et al.   Scientific Reports

Smart Nanodevice Combined Tumor-Specific Vector with Cellular Microenvironment-Triggered Property for Highly Effective Antiglioma Therapy

(2014) Kun Shao et al.   ACS Nano

Nanoparticle-Based Immunotherapy for Cancer

(2014) Kun Shao et al.   ACS Nano

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Tuning of Antigen Sensitivity by T Cell Receptor-Dependent Negative Feedback Controls T Cell Effector Function in Inflamed Tissues

(2014) Tetsuya Honda et al.   IMMUNITY

RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance

(2014) Yanping Xiao et al.   JOURNAL OF EXPERIMENTAL MEDICINE

B7H1/CD80 Interaction Augments PD-1–Dependent T Cell Apoptosis and Ameliorates Graft-versus-Host Disease

(2014) Ruishu Deng et al.   JOURNAL OF IMMUNOLOGY

pH-sensitive polymeric nanoparticles for tumor-targeting doxorubicin delivery: concept and recent advances

(2014) Fenghua Meng et al.   Nanomedicine

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

CD80 and PD-L2 define functionally distinct memory B cell subsets that are independent of antibody isotype

(2014) Griselda V Zuccarino-Catania et al.   NATURE IMMUNOLOGY

The immune checkpoint inhibitors: where are we now?

(2014) Rachel M. Webster   NATURE REVIEWS DRUG DISCOVERY

Nanoparticle approaches against bacterial infections

(2014) Weiwei Gao et al.   Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology

In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

(2014) C. Wang et al.   Cancer Immunology Research

Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes

(2014) L. Jeanbart et al.   Cancer Immunology Research

pH-Responsive Nanoparticle Vaccines for Dual-Delivery of Antigens and Immunostimulatory Oligonucleotides

(2013) John T. Wilson et al.   ACS Nano

Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer

(2013) Christian J. Maine et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology

(2013) U. Prabhakar et al.   CANCER RESEARCH

Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma

(2013) Y. Feng et al.   CLINICAL CANCER RESEARCH

Chemokine receptor CXCR4: Role in gastrointestinal cancer

(2013) Lucia Lombardi et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Structure and Interactions of the Human Programmed Cell Death 1 Receptor

(2013) Xiaoxiao Cheng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma

(2013) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Codelivery of VEGF siRNA and Gemcitabine Monophosphate in a Single Nanoparticle Formulation for Effective Treatment of NSCLC

(2013) Yuan Zhang et al.   MOLECULAR THERAPY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Polyethylenimines for siRNA and miRNA delivery in vivo

(2013) Sabrina Höbel et al.   Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology

Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells

(2012) E. F. Tewalt et al.   BLOOD

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

(2012) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia

(2012) Susan O'Brien et al.   JOURNAL OF CLINICAL ONCOLOGY

Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?

(2012) Sebastien Taurin et al.   JOURNAL OF CONTROLLED RELEASE

A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases

(2012) Mark J. Ernsting et al.   JOURNAL OF CONTROLLED RELEASE

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

(2012) Tadashi Yokosuka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation

(2012) N. Patsoukis et al.   Science Signaling

Micro and Nanoparticle-Based Delivery Systems for Vaccine Immunotherapy: An Immunological and Materials Perspective

(2012) Jardin Leleux et al.   Advanced Healthcare Materials

Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells

(2011) D. J. Andorsky et al.   CLINICAL CANCER RESEARCH

Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor

(2011) Jun Li et al.   JOURNAL OF CONTROLLED RELEASE

Lipoic Acid Modified Low Molecular Weight Polyethylenimine Mediates Nontoxic and Highly Potentin VitroGene Transfection

(2011) Meng Zheng et al.   MOLECULAR PHARMACEUTICS

Programming the magnitude and persistence of antibody responses with innate immunity

(2011) Sudhir Pai Kasturi et al.   NATURE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

(2011) Michael A. Curran et al.   PLoS One

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia

(2010) Q. Zhou et al.   BLOOD

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

(2010) J.-J. Park et al.   BLOOD

Overall survival and PD-L1 expression in metastasized malignant melanoma

(2010) Jules Gadiot et al.   CANCER

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

To PEGylate or not to PEGylate, that is not the question

(2010) Kinam Park   JOURNAL OF CONTROLLED RELEASE

Local Release of Highly Loaded Antibodies from Functionalized Nanoporous Support for Cancer Immunotherapy

(2010) Chenghong Lei et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity

(2010) N. Jain et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Synthetic therapeutic peptides: science and market

(2009) Patrick Vlieghe et al.   DRUG DISCOVERY TODAY

CD28 and CTLA-4 coreceptor expression and signal transduction

(2009) Christopher E. Rudd et al.   IMMUNOLOGICAL REVIEWS

Missing pieces in understanding the intracellular trafficking of polycation/DNA complexes

(2009) You-Yeon Won et al.   JOURNAL OF CONTROLLED RELEASE

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

(2009) Loise M. Francisco et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mediating Tumor Targeting Efficiency of Nanoparticles Through Design

(2009) Steven D. Perrault et al.   NANO LETTERS

CTLA-4 suppresses the pathogenicity of self antigen–specific T cells by cell-intrinsic and cell-extrinsic mechanisms

(2009) Wataru Ise et al.   NATURE IMMUNOLOGY

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal

(2009) Brian T Fife et al.   NATURE IMMUNOLOGY

Therapeutic Nanoparticles for Drug Delivery in Cancer

(2008) K. Cho et al.   CLINICAL CANCER RESEARCH

Interaction of human PD-L1 and B7-1

(2008) Manish J. Butte et al.   MOLECULAR IMMUNOLOGY

Enhancing SIV-specific immunity in vivo by PD-1 blockade

(2008) Vijayakumar Velu et al.   NATURE

Nanoparticle-mediated cellular response is size-dependent

(2008) Wen Jiang et al.   Nature Nanotechnology

Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation

(2008) Y. Onishi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CTLA-4 Control over Foxp3+ Regulatory T Cell Function

(2008) K. Wing et al.   SCIENCE

CTLA-4 trafficking and surface expression

(2008) Elke Valk et al.   TRENDS IN IMMUNOLOGY